BAY 2666605 是一种具有口服活性的 PDE3A 和 PDE3B 抑制剂，IC50 分别为 87 nM 和 50 nM。 BAY 2666605 具有抗癌作用。

BAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.

BAY 2666605 inhibits brain cancer(glioma, more specifically glioblastoma, astrocytoma), breast cancer (ductal carcinoma and adenocarcinoma), cervical cancer, AML(erythroleukemia), lung cancer(NSCLC adenocarcinoma and SCLC), skin cancer(melanoma), esophagus cancer (squamous cell carcinoma), ovarian cancer, (teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer[1].

In murine xenotransplantation models of human cancer, BAY 2666605 (5 mg/kg; p.o) exhibits anti-tumor efficacy[1].

2275774-60-0

C17H12F4N2O2

352.28

DMSO:245 mg/mL (695.47 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years